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Abstract
Background: Depression is a leading cause of disability worldwide and depressive symptoms are common in later
life. Observational evidence suggests that depression is more prevalent among people with high plasma
homocysteine (tHcy), but the results of randomized trials to date have been unable to show that lowering tHcy
through the supplementation of vitamins B6,B 12 and folate benefits depressive symptoms. We designed the B-
VITAGE trial to determine whether adjunctive treatment with vitamins B6,B 12 and folate increases the efficacy of
standard antidepressant treatment.
Methods/Design: The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily
citalopram (20 to 40 mg) plus B12(0.4 mg), B6 (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus
placebo for the treatment of depression in later life. The trial aims to recruit over 300 older adults with major
depression (DSM-IV) and has been powered to detect the impact of an intervention associated with moderate
effect size. Depressive symptoms will be rated with the Montgomery-Åsberg Depression Rating Scale (MADRS). The
trial has two main outcomes of interest: a reduction of 50% or more in the MADRS total score between baseline
and week 12 and the remission of the depressive episode at weeks 12, 26 and 52 according to DSM-IV criteria. We
hypothesize that subjects randomly allocated to the vitamin arm of the study will be more likely to show a
clinically significant improvement and achieve and maintain remission of symptoms at 12, 26 and 52 weeks.
Secondary outcomes of interest include compliance with treatment, reduction in the severity of depressive
symptoms, switching to different antidepressants, the use of non-pharmacological antidepressant treatments,
response to treatment according to MTHFRC677T genotype, and changes in cognitive function over 52 weeks.
Conclusions: The results of this trial will clarify whether the systematic use of B-vitamins improves the response of
older adults to standard antidepressant treatment. We anticipate that our findings will have implications for clinical
practice and health policy development.
Trial Registration: The trial is registered with the Australian Clinical Trials Registry, trial number (())
ACTRN12609000256279.
Background
Depression is a leading cause of disability worldwide [1]
and depressive symptoms are a common occurrence in
later life [2]. The causes of depression in later life are
likely to be varied and complex but current available
evidence suggests that cardiovascular risk factors and
diseases may be involved [3]. Total plasma homocys-
teine (tHcy) has been implicated as a risk factor for car-
diovascular disease [4] and more recently associated
with depression in later life [5].
The observation that B-vitamins and tHcy may be
associated with depression was initially described in the
1970’s by Reynolds and colleagues [6]. Substantial obser-
vational data from various sources has since been gath-
ered in support of this association, including nine cross-
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with depression have higher tHcy than their non-
depressed peers [5,7-14]. A recent meta-analysis of all
observational studies [5] designed to investigate the
association between tHcy and depression in later life
showed that high plasma tHcy was associated with an
increase in the odds of depression (OR = 1.70, 95%CI =
1.38 - 2.08; fixed effects model).
Homocysteine is a sulfur-containing amino acid
derived from the essential amino acid methionine
through demethylation [15]. Total plasma homocysteine
can be reliably reduced by the simple supplementation
of vitamins B12,B 6 and folic acid [16] which are all
involved in the metabolism of homocysteine through
two different pathways.
Homocysteine can be remethylated to methionine via
the 5-methyl-tetrahydrofolate pathway that is mediated
by the 5,10-methylenetetrahydrofolate reductase
(MTHFR) enzyme and requires B12 and folic acid, or
condensed with serine to form cysthionine in a reaction
that uses vitamin B6 [17]. Methionine is the immediate
precursor of S-adenosylmethionine (SAM), the methyl
donor of numerous methylation reactions in the brain,
many of which are directly involved in the synthesis and
metabolism of monoamines such as dopamine, norepi-
nephrine and serotonin [9]. This suggests that the asso-
ciation between elevated homocysteine and depression
is biologically plausible.
Another way of investigating the association between
tHcy and depression is via the MTHFR gene. MTHFR
converts 5,10-methylene tetrahydrofolate to 5-methylte-
trahydrofolate which is needed for the remethylation of
homocysteine to methionine. Approximately 10% of the
population is homozygous for the 677 C®T polymorph-
ism of the MTHFR gene. This polymorphism reduces
the production of 5-methyltetrahydrofolate and thus
increases total plasma homocysteine by around 20%
(approximately 2 μmol/L) [18]. We examined the asso-
ciation between MTHFR C677T genotype, tHcy and
clinical history of ever depression in the Health in Men
Study (HIMS) cohort [5]. We found that tHcy was 1.4
μmol/L higher amongst TT than CC carriers. We then
conducted a meta-analysis of studies investigating the
association between depression and MTHFR genotype,
including our own data from HIMS. Overall TT carriers
had a 22% increase in the odds of depression compared
with CC carriers (OR = 1.22, 95%CI = 1.01 - 1.47).
Observational evidence would therefore support a cau-
sal link between high plasma homocysteine and depres-
sion. The most compelling way to establish causality
however, is by means of randomized controlled trials
where depressed older adults are exposed to homocys-
teine-lowering treatment or placebo. Seven clinical trials
reported the results of homocysteine-lowering treatment
on the mood of people with depression [19-25].
Together, these studies evaluated the effect of some
form of B-vitamin supplementation in a heterogeneous
group of 788 patients, some of them without clinically
significant depression. Their results suggest that folate
supplementation may have a role to play in the adjunc-
tive treatment of depression, although the number of
patients studied to date is small and the reported bene-
fits associated with B-vitamin treatment are mostly
based on post hoc comparisons of subgroups of patients
(for example, women but not men).
The results from clinical trials to date are therefore
modest at best and do not adequately support the find-
ings of observational research. These seven studies were
small in size and some were obviously underpowered to
detect smaller clinically significant changes in mood.
The trials were heterogeneous in nature and recruited
p a r t i c i p a n t sw i t haw i d ea g er a n g ea n ds e v e r i t yo f
depressive symptoms. Older adults have a higher risk of
cerebrovascular disease and are therefore a group that
may benefit more from homocysteine-lowering treat-
ment given the hypothesized link between cerebrovascu-
lar disease and depression [3]. Trial durations also
varied and most available studies were too brief to pro-
duce useful information about the clinical implications
of longer periods of supplementation.
The B-VITAGE trial aims to recruit a community-
representative sample of over 300 older adults (age 60
and older) who will be randomly allocated to treatment
with citalopram and vitamins or citalopram and placebo
in a double blind fashion for 12 weeks. Citalopram was
chosen due to its relatively low incidence of adverse
effects, favorable safety profile and relatively low risk of
drug interactions [26]. After 12 weeks, the antidepres-
sant management of participants will be devolved to
their general practitioner. Blinded treatment with vita-
mins and placebo will remain unchanged for 52 weeks.
We hypothesize that older adults randomized to
receive citalopram and vitamins B12,B 6 and folic acid
will be more likely to show a clinically significant reduc-
tion in the severity of depressive symptoms over 12
weeks. Additionally, we hypothesize that participants in
the vitamin group will be more likely to achieve and
sustain remission of their depression over 12 months.
The study will also aim to investigate whether MTHFR
carrier status has any impact on response to supplemen-
tation with B vitamins (secondary aim).
Methods/Design
Study Design
The B-VITAGE trial is a 12-month randomized, double-
blind, placebo-controlled trial of citalopram plus vitamin
B12,B 6 and folic acid or citalopram plus placebo for the
treatment of depression in later life. The Human
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approved the study protocol. Recruitment is currently
ongoing. The trial is investigator driven and will be
coordinated by the principle investigator (OPA). A
steering committee consisting of the lead investigators,
study coordinator and research assistant will meet on a
monthly basis to oversee the running of the trial.
Setting
Participants will be treated as outpatients at the Royal
Perth Hospital Mood Disorder Clinic in Western Aus-
tralia, Australia. Taxi vouchers will be provided for tra-
vel to and from the hospital if required. Remuneration
for participants’ time will not be provided.
Eligibility Criteria
Participants will be included if they:
1. are aged 60 years or older,
2. satisfy the DSM-IV [27] criteria for a major depres-
sive episode in the context of a major depressive disor-
der (recurrent or single episode),
3. have a Montgomery-Åsberg Depression Rating Scale
(MADRS) [28] score of 20 or greater (moderate or
severe depression),
4. are fluent in written and spoken English.
We will exclude from the trial older adults who:
1. show evidence of risky alcohol use as judged by an
Alcohol Use Disorders Identification Test (AUDIT) [29]
score greater than 15,
2. have Parkinson’s disease or a documented clinical
history of stroke,
3. show evidence of clinically significant cognitive
impairment (Mini-Mental State Examination - MMSE
[30] score lower than 24),
4. are actively suicidal or display prominent psychotic
symptoms,
5. have a life-threatening illness that is likely to com-
promise 12-month survival,
6. are unable to follow the research schedule,
7. are currently being treated with a monoamine oxi-
dase inhibitor or electroconvulsive therapy,
8. have a clinical history of an allergic reaction to cita-
lopram or escitalopram,
9. do not provide written informed consent.
Participants taking an antidepressant will not be
excluded provided they fulfil the entry criteria (i.e., fail
to respond to a trial with another antidepressant) and
agree to change the medication to citalopram. In this
case, citalopram will be commenced after a one-week
washout period to minimize carryover effects from the
existing antidepressant while minimizing the risk of
deterioration in the mental state of participants that
could potentially occur with longer washout periods.
We will also include in the study older adults taking
vitamins as long as they agree to discontinue their use
for the duration of the trial.
The local Ethics Committee questioned the inclusion
of participants with a baseline serum B12 <140 pmol/L
who drink alcohol, as they could potentially be ran-
domly allocated to treatment with placebo. As a result
of these discussions, the B-VITAGE trial will also
exclude from participation older adults who have an
AUDIT score greater than 7 and a serum concentration
of methylmalonic acid (MMA) >0.4 μmol/L. MMA is a
tissue marker of vitamin B12 deficiency [31].
Screening and Recruitment Strategies
We have been using five different approaches to screen
and recruit community-dwelling older adults with
depression:
1. General practitioners in the Perth Metropolitan
Area are currently being approached and asked to parti-
cipate. They will be requested to send an invitation to
all their older patients (60+) who have consulted them
in the past 12 months. The mail out will include an
invitation letter, the Patient Health Questionnaire
(PHQ-9), [32] the AUDIT, a consent form and informa-
tion about the study. Potential participants will be asked
to return the completed PHQ-9, AUDIT and consent
form to the study team if they wish to participate.
2. The Western Australian Centre for Health and Age-
ing have access to large databases of potential partici-
pants from previous studies (DEPS-GP, [33] n = 4305
and HIMS, [34] n ≈ 7500) and these will be utilized to
aid recruitment. Participants from these studies who
have indicated that they would be happy to have future
contact with the Centre will be invited to participate.
3. Older Adult Mental Health Services in metropolitan
Perth receive approximately 2000 referrals per year, of
which roughly 1000 are due to a depressive episode. We
estimate that approximately 500 of these patients will be
eligible (estimate based on clinical audit of the Inner
City Older Adult Mental Health Service) and that 30%
will consent to participate. Referrals will therefore be
sought from these services.
4. Public advertising campaign. The study will be
widely publicized in the media including community
newspapers. We will also be distributing flyers in some
GP practices and community organizations.
5. The last recruitment strategy will involve contacting
individual GPs and seeking referrals directly to the
clinic. This will be offered as an assessment service and
suitable consenting patients will be enrolled.
Anyone who screens positive on the PHQ (i.e. scores
10 or higher) will be contacted by the research staff
upon receiving the questionnaire and invited to attend a
clinic appointment within 2 weeks. Patients who decline
to participate will be referred to their general practi-
tioners who will be informed of the results of their
screening questionnaires. We anticipate that the recruit-
ment of participants will be completed by the end of
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end of 2012. Clinical records will be managed as per
existing hospital policies and participant information
kept confidential at all times.
Objectives
1) Clinically significant improvement in the severity of
depressive symptoms
One primary outcome of interest in this study is a
reduction of 50% or more in the MADRS total score
between baseline and week 12 which is considered to be
of clinical significance. Our hypothesis is that partici-
pants randomly allocated to treatment with vitamins
will be more likely than placebo control subjects to
show a clinically significant reduction in the severity of
depressive symptoms between baseline and week 12.
2) Remission from index depressive episode
The other primary outcome of interest in this trial is the
remission of the depressive episode at weeks 12, 26 and
52 according to DSM-IV criteria i.e. the participant no
longer meets the diagnostic criteria for a diagnosis of
major depression. Our hypothesis is that participants in
the vitamin group will be more likely to achieve and
maintain remission of their depression.
Secondary outcomes of interest include compliance
with treatment, changes in the MADRS scores from
baseline to week 12 (i.e. difference between the groups
in their mean change from baseline MADRS scores as a
continuous measure), switching to different antidepres-
sants, the use of non-pharmacological antidepressant
treatment (such as psychotherapy), response to treat-
ment according to MTHFRC677T genotype, and




Potential participants will be screened with the PHQ-9,
a widely used and well-accepted screening instrument
for depression. A PHQ-9 total score of 10 or more is
associated with 88% sensitivity and specificity for a diag-
nosis of a depressive episode according to DSM-IV cri-
teria. The PHQ-9 is a simple and easy to use instrument
that takes no longer than 3 minutes to complete.
Risk alcohol use
the AUDIT is a 10-item questionnaire designed to
screen for excessive drinking. The scale takes 2 minutes
to complete, with scores greater than 15 being indicative
of alcohol dependency.
Cognitive impairment and function
we will use the Mini-Mental State Examination (MMSE)
to assess the cognitive abilities of participants and this
will be administered by the research staff during the
baseline clinic assessment.T h o s ew i t has c o r el o w e r
than 24 will be excluded from further participation due
to the presence of cognitive impairment. In addition,
trained research staff will administer the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
[35] neuropsychology battery.
Establishing the diagnosis of a major depressive episode
We will use the Mini-International Neuropsychiatric
Interview (M.I.N.I.) to assess the current mental state of
participants as well as their prior mental health history
[36]. The M.I.N.I. is a short structured clinical interview
that can be administered by trained research staff. It
provides all relevant information to establish the diagno-
sis of a depressive episode according to DSM-IV criteria.
Measuring the severity of depressive symptoms
Participants will undergo a psychiatric assessment with
one of the three study psychiatrists who will use the
Montgomery-Åsberg Depression Rating Scale (MADRS)
to measure the severity of depressive symptoms. The
MADRS is widely used in clinical trials of depression
because it is demonstrably sensitive to change. The
MADRS will be rated at baseline, week 4, 8, 12, 26 and
52. The scale takes approximately 10-15 minutes to rate.
The M.I.N.I. and MADRS will measure the two pri-
mary outcomes of interest (i.e. clinically relevant
improvement and remission of depressive symptoms).
Medical morbidities, lifestyle and medications
We will collect information from participants regarding
current and past medical history and current medica-
tions. We will also record basic demographic informa-
tion (date of birth, marital status, educational
achievement and living arrangements) and will measure
weight, height, blood pressure and pulse rate using stan-
dard procedures.
Monitoring of adverse reactions and events
We will use the Systematic Assessment for Treatment
Emergent Effects [37] (Saftee) to monitor for any
adverse reactions associated with the use of citalopram
and vitamins or placebo. For the purposes of this study
this will involve a checklist of symptoms commonly
associated with experimental medications and antide-
pressants in particular, such as tremor, headaches, anxi-
ety, insomnia, gastrointestinal symptoms and sexual
side-effects, as well questions about painful peripheral
neuropathy which can rarely be associated with exces-
sive vitamin B6 use [38]. The participant will be asked
about the emergence of any new symptoms since the
last assessment and these will be rated on a 4 point
scale - not at all, a little, quite a bit and extremely. The
checklist will be completed during each clinic visit. The
investigators will use this to screen for any new symp-
toms which could be attributed to the study medication
as well as to monitor for any changes in the pattern and
intensity of symptoms.
An unblinded geriatrician (LF) will independently
monitor the blood results and any significant adverse
events. He will notify the participant and their general
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will notify the Ethics Committee in the event of any ser-
ious adverse event and unblinding of the investigators
will occur.
Biochemistry tests
Fasting blood samples will be collected at baseline and
again at weeks 12, 26 and 52 for the assessment of
serum B12 and red cell folate (measured by standard
competitive assays using the Abbott Axsym analyzer), as
well as plasma homocysteine (measured by reverse
phase high performance liquid chromatography after
treatment with tributylphosphine, deproteinization and
fluorogenic derivatization using the method of Araki
and Sako) [39].
Genetics
Genomic DNA will be isolated from nucleated blood
cells via a Triton X-100 method, and the 677 C ® T
mutation will be determined by use of the polymerase
chain reaction (PCR) and HinfI restriction enzyme
digestion as described by Frosst et al. [40]HinfI digestion
(1.5 U/25 μL reaction mixture) will be performed
directly in the PCR tube at 37°C for 4 hours before ana-
lysis of restriction fragments by polyacrylamide gel elec-
trophoresis (PAGE; 12% T, 3.3% C) [41]. Allele
frequencies will be estimated by gene counting and
observed numbers of each genotype will be compared
with those expected under Hardy-Weinberg equilibrium.
We will aim to clarify if the clinical response to vitamin
treatment is affected by MTHFR genotype.
Sample Size
We based our sample size calculations to test hypothesis
1 on the results of the trial published by Coppen and
Bailey, [22] which is the largest study of adjunctive anti-
depressant treatment with folic acid published to date.
This study also enrolled a community-representative
sample although recruited adults 18 years and over. The
B-VITAGE trial will therefore have the added potential
advantage of having participants with higher average
tHcy given their older age (60 plus). We have previously
shown that tHcy increases with age and that response to
homocysteine-lowering vitamins is higher in people with
higher tHcy [17]. Fluoxetine and citalopram are both
selective serotonin reuptake inhibitors (SSRI’s) and have
been shown to have similar efficacy in the treatment of
major depression [42]. The addition of vitamins B12 and
B6 in our study may provide additional benefit (and
therefore potentially bigger effect sizes) than folate sup-
plementation alone given their respective roles in homo-
cysteine metabolism.
Coppen and Bailey reported that 64.7% of their sub-
jects treated with fluoxetine 20 mg and folic acid 0.5 mg
were free of clinically significant depressive symptoms at
the end of 10 weeks (Hamilton Depression Rating Scale
score = 9), compared with 48.3% of those receiving
fluoxetine 20 mg and placebo. A difference in remission
rates of this magnitude is considered to be of meaning-
ful clinical significance [43]. A study with 310 subjects
(155 per group) would have 80% power to demonstrate
a difference of this magnitude, with 2-tailed alpha set at
5%. We conservatively estimate a 12-week loss to fol-
low-up of 15%, with an additional 10% lost between
weeks 12 and 52 (total loss of 25%). Therefore, we will
aim to recruit 388 older adults with a depressive episode
into the trial (194 subjects per group).
To estimate the power of our study to test hypothesis
2, we used previously published data showing that about
35% of older adults with depression either remain
depressed or relapse during the first year of treatment
[44]. A study with 155 subjects per group by the end of
12 months will have 81% power to declare as significant
a between group difference of 15% (35% vs 20% for pla-
cebo and vitamins, respectively). Finally, a study of this
size will have 80% power to declare as significant a
mean difference of MADRS scores between the groups
of 2.3 points (standard deviation = 7, alpha = 0.05) [45].
Changes in the scores of the MADRS between baseline
and week 12 will constitute a secondary outcome of
interest for the study.
Randomization
Participants will be given consecutive numbers and will
be allocated to treatment with citalopram plus B-vita-
mins or citalopram plus placebo according to a list of
random numbers generated by computer in random
permuted blocks of 6 to 16. This strategy decreases the
risk of unblinding of participants in one particular block
if, for some reason, the group membership of one of its
members is disclosed. The list will be generated and
maintained centrally by the Pharmacy at the Royal Perth
Hospital until the last assessment of the study is
completed.
Intervention and Blinding
Eligible participants will be randomly allocated to
treatment with citalopram plus 400 μgv i t a m i nB 12,2
mg folic acid and 25 mg B6 or citalopram plus placebo.
These doses have been shown to be effective in lower-
ing homocysteine levels [17]. Citalopram will be intro-
duced at a dose of 10 mg per day and increased to 20
mg per day after 2 weeks. After 4 weeks of treatment
t h ed o s eo fc i t a l o p r a mw i l lb ei n c r e a s e dt o3 0m gf o r
those who still meet DSM-IV criteria for a depressive
episode (i.e., partial or no response) and again to 40
mg at week 8, if appropriate (i.e., participant remains
depressed and has not displayed significant adverse
events that would rule out an increase in dose). After
12 weeks, the antidepressant management of partici-
pants will be devolved to their general practitioner.
Blinded treatment with vitamins and placebo will
remain unchanged for 52 weeks.
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citalopram tablets as prescribed by the study psychia-
trists. Vitamins and placebo will be administered in the
form of one daily oral capsule that will have the same
shape, size, color, texture and taste. The capsules con-
taining B-vitamins and placebo will be manufactured by
Blackmores, Australia. The Pharmacy will be responsible
for dispensing all study medication and will monitor
compliance by pill counting. Compliance will be moni-
tored further by regular assessment of the serum con-
centration of B12 and folate (these results will only be
released to the blinded investigators by the Royal Perth
Hospital Biochemistry Laboratory after the last study
assessment is completed).
Assessment Procedures
Participants will be asked to attend the study clinic on
six occasions: baseline, 4, 8, 12, 26 and 52 weeks. Parti-
cipants will be asked to complete a PHQ-9, AUDIT and
consent form to screen for potential eligibility prior to
attending a baseline assessment. Fasting blood will be
collected at baseline as well as weeks 12, 26 and 52. A
trained research assistant will administer an abbreviated
(for the purpose of the study’s objectives) version of the
M.I.N.I. focussing on current and past episodes of
depression, mania/hypomania, dysthymia and suicidality.
All potential participants will then be assessed by one of
the study psychiatrists who will administer the MADRS.
The MADRS will be repeated during each visit whilst
the M.I.N.I. will be administered at baseline, week 12,
26 and 52.
Participant’s general practitioners will receive a letter
from one of the study psychiatrists following each visit
to keep them updated about the progress of their
patient and to inform them of the outcome of the var-
ious assessments. Advice will be provided about further
treatment if needed e.g. treatment of excessive alcohol
use, alerting them to the presence of suicidal ideation or
psychotic symptoms and suggesting further assessment
of cognitive impairment. The table outlines the assess-
ment schedule of the B-VITAGE trial (Table 1).
Statistical Analysis
Analyses will be conducted based on completers and
intention-to-treat. Hypotheses 1 and 2 will be tested
using the Pearson’s chi-square statistic (proportion of
people in the active and placebo groups who show a
reduction of 50% or more on the MADRS or who go
into remission). To account for the potential effects of
dropout, we will repeat our analysis using a mixed-
effects model for repeated measures [46] to model the
fixed categorical effects of treatment, time, and treat-
ment by time interaction, as well as the continuous,
fixed covariate of baseline MADRS score. In addition,
missing data will be imputed via Imputation by Chained
Equations (ICE) [47] in order to perform the intention-
to-treat analysis. Data will be maintained, managed and
analyzed using the statistical package Stata.
Discussion
Depression is often a chronic and disabling condition
[48] that does not always respond well to antidepressant
treatment [49]. This trial will determine if the use of B-
vitamins can improve the efficacy of antidepressant
treatment amongst older adults with depression. Exist-
ing evidence provides some justification for the addition
of folic acid to treatment with antidepressants [20,21,23]
although these trials have generally been of short dura-
tion and have been powered to detect large effect sizes
only. Previous studies have also enrolled younger parti-
cipants who have not necessarily met criteria for major
depression.
The design of this study has strengths and limitations
that merit comment. Firstly, the study is not limited to
older adults with elevated total plasma homocysteine
and this may raise concerns about the power of the
study. We have previously demonstrated that the use of
B-vitamins reduces total plasma homocysteine amongst
those with or without high homocysteine and those with
or without low serum concentration of vitamins B12 and
folate [17]. Consequently, the trial is unlikely to be lim-
ited by lack of efficacy of the intervention to reduce
total plasma homocysteine. Secondly, it is possible that
the ‘depressogenic effect’ of homocysteine is cumulative
a n dt h a ta1 2 - w e e kt r i a li sn o ts u f f i c i e n t l yl o n gt op r o -
mote the changes associated with reduced tHcy (hypoth-
esis 1). We cannot entirely dismiss this possibility, but
c u r r e n t l ya v a i l a b l ee v i d e n c ef r o mo t h e rt r i a l so f6t o1 0
weeks duration suggests this is unlikely to be the case
[22-24]. In addition, the ongoing follow-up of partici-
pants for 12 months will enable us to monitor the
longer term effects of B-vitamin supplementation on
mood.
At h i r dp o s s i b l ec o n c e r nm a yb et h ei m p a c to fp r e -
existing antidepressant or vitamin treatment as well as
other non-pharmacological treatments (e.g. psychother-
apy) that participants may be exposed to. Whilst these
may indeed have some impact on the outcomes for indi-
vidual participants, the process of randomization should
hopefully ensure an even distribution of these potential
confounders in the two arms. Fourth, there is a possibi-
lity that discontinuation rates of vitamins may increase
after the more intensive monitoring period of the first
12 weeks of the trial and rates may be higher in the
intervention group presuming the hypothesis of
improved outcomes in this group is accurate. This will
be monitored via pill counts, blood tests and medication
diaries with participants given prompts about compli-
ance during each visit. Finally, questions may arise
regarding the changes in antidepressant treatment that
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fere with the outcomes of the trial. Changes in antide-
pressant treatment may not be randomly distributed
between the two treatment groups and for this reason
we will monitor changes of medications and dose for
the duration of the trial.
These potential limitations should be seen in the con-
text of the strengths of this trial. We will be enrolling
older adults who are perhaps the group who may benefit
most from homocysteine-lowering treatment. The trial
has well-defined outcomes and is adequately powered to
study these. The trial will be run over 12 months and
will involve a community sample of participants
recruited from a variety of clinical and non-clinical set-
tings. All participants will meet the criteria for a major
depressive episode.
It is envisaged that the results of this trial will add
further evidence to the homocysteine-depression link
and potentially help guide treatment decisions for older
adults with depression.
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